Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2CTx-1301 is the First, True, Once-Daily Stimulant Medication to ...

Cingulate (CING) released Phase 3 safety data for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD.

Compass Therapeutics, Inc.’s CMPX share price has dipped by 11.90%, which has investors questioning if this is right time to buy.

The FDA on Friday gave the green light to Mirum’s Ctexli, also known as chenodiol, for the treatment of adults with cerebrotendinous xanthomatosis (CTX). The approval makes chenodiol—already ...

Cingulate Inc. submitted CTx-1301 Phase 3 safety data to the FDA, preparing for a Pre-NDA meeting on April 2, 2025. Cingulate Inc. announced the submission of Phase 3 safety data for its ADHD ...

#include <stdio.h> #include <signal.h> #include <execinfo.h> void bt_sighandler(int sig, struct sigcontext ctx) { void *trace[16]; char **messages = (char **)NULL ...

(Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLI™ (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis ...

“The safety data from these three studies has been reviewed thoroughly, and we are pleased that the safety profile of CTx-1301 has remained remarkably consistent and unprecedented over the ...